News >

Bazhenova Highlights Treatments for ALK+ NSCLC, Less Common Drivers

Caroline Seymour
Published: Thursday, Jun 28, 2018

Lyudmila A. Bazhenova, MD

Lyudmila A. Bazhenova, MD
Alectinib (Alecensa) is the frontline de-facto standard of care for patients with ALK-positive non–small cell lung cancer (NSCLC), said Lyudmila A. Bazhenova, MD. Exploration into mechanisms of resistance will help physicians unveil how to best sequence available therapies.


OncLive: Please discuss the recent questions in ALK-positive NSCLC.

Bazhenova: My lecture about ALK-positive lung cancer concentrates on sequencing strategies. We now have more than 1 ALK inhibitor approved in lung cancer. The common questions that come up are, “How do we sequence them? What is the right first-line and second-line ALK inhibitor?” And [we need to know] whether you need to do a postprogression biopsy to understand the mechanism of resistance to ALK inhibition.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication